ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 1892 for:    "Alzheimer disease familial"

Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03408041
Recruitment Status : Completed
First Posted : January 23, 2018
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Murielle Surquin, Brugmann University Hospital

Brief Summary:

The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease.

The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.


Condition or disease Intervention/treatment
Alzheimer Disease Other: Medical file data extraction

Study Type : Observational
Actual Enrollment : 129 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters
Actual Study Start Date : May 1, 2016
Actual Primary Completion Date : October 1, 2017
Actual Study Completion Date : October 1, 2017

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Alzheimer Disease
Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
Other: Medical file data extraction
Medical file data extraction




Primary Outcome Measures :
  1. Age [ Time Frame: Between 01-01-2010 and 31-01-2013 ]
    Age

  2. Sex [ Time Frame: Between 01-01-2010 and 31-01-2013 ]
    Sex

  3. Ethnic origin [ Time Frame: Between 01-01-2010 and 31-01-2013 ]
    Ethnic origin

  4. Symptoms-diagnose time interval [ Time Frame: Between 01-01-2010 and 31-01-2013 ]
    Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.

  5. Scheltens scale [ Time Frame: Between 01-01-2010 and 31-01-2013 ]
    Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
Criteria

Inclusion Criteria:

Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03408041


Locations
Belgium
CHU Brugmann
Brussels, Belgium
Sponsors and Collaborators
Murielle Surquin
Investigators
Principal Investigator: Florence Benoit, MD CHU Brugmann

Responsible Party: Murielle Surquin, Head of clinic, Brugmann University Hospital
ClinicalTrials.gov Identifier: NCT03408041     History of Changes
Other Study ID Numbers: CHUB-parameters Alzheimer
First Posted: January 23, 2018    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Murielle Surquin, Brugmann University Hospital:
Alzheimer Disease
Objective parameters
Scheltens index

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders